EFS and OS of patients with previously untreated MM with IGF-1R^absent or IGF-1R^present with or without spiked MMSET MMCs and with IL-6R^low and IL-6R^high with or without spiked MMSET MMCs. Spiked MMSET was determined with Affymetrix U133 microarrays in the patients from HM series and LR-TT2 series (Spiked MMSET expression surrogating t(4;14)). In HM series, 112 patients had IGF-1R^absent MMCs, 33 IGF-1R^present without spiked MMSET MMCs and 20 IGF-1R^present with spiked MMSET MMCs. A total of 79 patients had IL-6R^low MMCs, 65 IL-6R^high without spiked MMSET MMCs, and 20 IL-6R^high with spiked MMSET MMCs. In the LR-TT2 series, 170 patients had IGF-1R^absent MMCs, 126 IGF-1R^present without spiked MMSET MMCs, and 46 IGF-1R^present with spiked MMSET MMCs. A total of 163 patients had IL-6R^low MMCs, 132 IL-6R^high without spiked MMSET MMCs, and 40 IL-6R^high with spiked MMSET MMCs. EFS of IGF-1R^absent MMCs and IGF-1R^present with or without spiked MMSET MMCs patients from the HM series (A) and from the LR-TT2 series (B). OS of IGF-1R^absent MMCs and IGF-1R^present with or without spiked MMSET MMC patients from the HM series (C) and from the LR-TT2 series (D). The P value was determined with a log-rank test. EFS of IL-6R^low MMC and IL-6R^high with or without spiked MMSET MMC patients from the HM series (E) and from the LR-TT2 series (F). OS IL-6R^low MMC and IL-6R^high MMC with or without spiked MMSET patients from HM series (G) and from LR-TT2 series (H). The P value was determined with a log-rank test.